Article
Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
CPT: pharmacometrics & systems pharmacology - 1 Sept 2017
Diekstra M H, Fritsch A, Kanefendt F, Swen J J, Moes Djar, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney L A, Guchelaar H J, Jaehde U
Abstract excerpt
The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.